Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Actuate Therapeutics Q3 2026 Results: Net Loss of $3.42M, Loss Narrows

Actuate Therapeutics reported a net loss of $13.9 million for the nine months ended September 30, 2026, compared to $17.7 million in the prior year period. The company's cash position decreased significantly to $2.1 million, resulting in a working capital deficit and a stated going concern uncertainty as it continues to fund clinical development of elraglusib.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-3.4-5.4
EPS (diluted, $ a share)$-0.14$-0.25

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ACTU. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Actuate Therapeutics, Inc.: key numbers

Share price
$0.2516Close, Nov 17
Market cap
$15.2M
Shares outstanding
60.38MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Actuate Therapeutics, Inc.

All →
4:05 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Actuate Therapeutics Nasdaq/NYSE Compliance Notice

Actuate Therapeutics received a deficiency notice from Nasdaq because its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until April 26, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. This notice follows a separate July 2026 warning regarding the company's failure to meet the minimum market value of listed securities requirement.

Counterparty
The Nasdaq Stock Market LLC
Term
180 days
9:36 AM ET Form 4
Insider Buying

Actuate Therapeutics President, CEO and Director Daniel M. Schmitt Buys $50K of Stock

Daniel M. Schmitt, President, CEO and Director, bought 140,844 shares of Actuate Therapeutics, Inc. at $0.355 a share, worth $50K in total on Oct 28, 2026. Shares held after the trade: 442,560 (+46.7%).

Value
$50K
Shares
140,844
Price
$0.3550
Role
President, CEO and Director
Holding change
+46.7%
Trade date
Oct 28, 2026
5:17 PM ET 8-K
Capital Raise

Actuate Therapeutics Capital Raise of $11M

Actuate Therapeutics closed an underwritten public offering of 30,985,900 shares of common stock and warrants to purchase 15,492,950 shares, raising gross proceeds of approximately $11.0 million. The offering was priced at $0.71 per set of two shares and one warrant, implying a per-share price of $0.355. The company intends to use the net proceeds for working capital and general corporate purposes.

Value
$11M
Counterparty
Newbridge Securities Corporation

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.